Immunogenicity of recombinant type IX collagen in murine collagen-induced arthritis

Linda Myers, T. Pihlajamaa, David Brand, M. A. Cremer, M. Bodo, L. Ala-Kokko, Andrew Kang

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective. Past attempts to isolate type IX collagen (CIX) from cartilage using limited proteolysis yielded partially degraded material. Recent application of recombinant technology, however, has allowed the preparation of intact native CIX. We used the murine collagen-induced arthritis model to characterize the immunologic properties of recombinant human CIX (rCIX) produced using a baculovirus expression system. Methods. A panel of B10 congenic mice was immunized with rCIX emulsified with Freund's complete adjuvant (CFA). The ability of the rCIX to induce tolerance and suppress arthritis was determined by administration intravenously or orally before challenge with CII/CFA. Results. None of the mice immunized with rCIX developed overt arthritis, although 2 of 5 HLA-DR1 transgenic mice developed limited digital erythema and swelling. Recombinant CIX administered by either route effectively induced suppression of arthritis, although the suppression was less pronounced than that induced with CII. Immune responses to CIX and CII were specific, suggesting that bystander suppression, rather than cross-reactivity with CII, was instrumental in suppressing arthritis. Conclusion. These data show that CIX down-regulates arthritis in mice while having no associated risk of inducing arthritis.

Original languageEnglish (US)
Pages (from-to)1086-1093
Number of pages8
JournalArthritis and rheumatism
Volume46
Issue number4
DOIs
StatePublished - Apr 23 2002

Fingerprint

Collagen Type IX
Experimental Arthritis
Arthritis
HLA-DR1 Antigen
Bystander Effect
Congenic Mice
Freund's Adjuvant
Baculoviridae
Erythema
Transgenic Mice
Proteolysis
Cartilage
Down-Regulation
Technology

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Pharmacology (medical)

Cite this

Immunogenicity of recombinant type IX collagen in murine collagen-induced arthritis. / Myers, Linda; Pihlajamaa, T.; Brand, David; Cremer, M. A.; Bodo, M.; Ala-Kokko, L.; Kang, Andrew.

In: Arthritis and rheumatism, Vol. 46, No. 4, 23.04.2002, p. 1086-1093.

Research output: Contribution to journalArticle

Myers, Linda ; Pihlajamaa, T. ; Brand, David ; Cremer, M. A. ; Bodo, M. ; Ala-Kokko, L. ; Kang, Andrew. / Immunogenicity of recombinant type IX collagen in murine collagen-induced arthritis. In: Arthritis and rheumatism. 2002 ; Vol. 46, No. 4. pp. 1086-1093.
@article{c7baed6b86664079a4328f9d293b54d9,
title = "Immunogenicity of recombinant type IX collagen in murine collagen-induced arthritis",
abstract = "Objective. Past attempts to isolate type IX collagen (CIX) from cartilage using limited proteolysis yielded partially degraded material. Recent application of recombinant technology, however, has allowed the preparation of intact native CIX. We used the murine collagen-induced arthritis model to characterize the immunologic properties of recombinant human CIX (rCIX) produced using a baculovirus expression system. Methods. A panel of B10 congenic mice was immunized with rCIX emulsified with Freund's complete adjuvant (CFA). The ability of the rCIX to induce tolerance and suppress arthritis was determined by administration intravenously or orally before challenge with CII/CFA. Results. None of the mice immunized with rCIX developed overt arthritis, although 2 of 5 HLA-DR1 transgenic mice developed limited digital erythema and swelling. Recombinant CIX administered by either route effectively induced suppression of arthritis, although the suppression was less pronounced than that induced with CII. Immune responses to CIX and CII were specific, suggesting that bystander suppression, rather than cross-reactivity with CII, was instrumental in suppressing arthritis. Conclusion. These data show that CIX down-regulates arthritis in mice while having no associated risk of inducing arthritis.",
author = "Linda Myers and T. Pihlajamaa and David Brand and Cremer, {M. A.} and M. Bodo and L. Ala-Kokko and Andrew Kang",
year = "2002",
month = "4",
day = "23",
doi = "10.1002/art.10163",
language = "English (US)",
volume = "46",
pages = "1086--1093",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Immunogenicity of recombinant type IX collagen in murine collagen-induced arthritis

AU - Myers, Linda

AU - Pihlajamaa, T.

AU - Brand, David

AU - Cremer, M. A.

AU - Bodo, M.

AU - Ala-Kokko, L.

AU - Kang, Andrew

PY - 2002/4/23

Y1 - 2002/4/23

N2 - Objective. Past attempts to isolate type IX collagen (CIX) from cartilage using limited proteolysis yielded partially degraded material. Recent application of recombinant technology, however, has allowed the preparation of intact native CIX. We used the murine collagen-induced arthritis model to characterize the immunologic properties of recombinant human CIX (rCIX) produced using a baculovirus expression system. Methods. A panel of B10 congenic mice was immunized with rCIX emulsified with Freund's complete adjuvant (CFA). The ability of the rCIX to induce tolerance and suppress arthritis was determined by administration intravenously or orally before challenge with CII/CFA. Results. None of the mice immunized with rCIX developed overt arthritis, although 2 of 5 HLA-DR1 transgenic mice developed limited digital erythema and swelling. Recombinant CIX administered by either route effectively induced suppression of arthritis, although the suppression was less pronounced than that induced with CII. Immune responses to CIX and CII were specific, suggesting that bystander suppression, rather than cross-reactivity with CII, was instrumental in suppressing arthritis. Conclusion. These data show that CIX down-regulates arthritis in mice while having no associated risk of inducing arthritis.

AB - Objective. Past attempts to isolate type IX collagen (CIX) from cartilage using limited proteolysis yielded partially degraded material. Recent application of recombinant technology, however, has allowed the preparation of intact native CIX. We used the murine collagen-induced arthritis model to characterize the immunologic properties of recombinant human CIX (rCIX) produced using a baculovirus expression system. Methods. A panel of B10 congenic mice was immunized with rCIX emulsified with Freund's complete adjuvant (CFA). The ability of the rCIX to induce tolerance and suppress arthritis was determined by administration intravenously or orally before challenge with CII/CFA. Results. None of the mice immunized with rCIX developed overt arthritis, although 2 of 5 HLA-DR1 transgenic mice developed limited digital erythema and swelling. Recombinant CIX administered by either route effectively induced suppression of arthritis, although the suppression was less pronounced than that induced with CII. Immune responses to CIX and CII were specific, suggesting that bystander suppression, rather than cross-reactivity with CII, was instrumental in suppressing arthritis. Conclusion. These data show that CIX down-regulates arthritis in mice while having no associated risk of inducing arthritis.

UR - http://www.scopus.com/inward/record.url?scp=0036229092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036229092&partnerID=8YFLogxK

U2 - 10.1002/art.10163

DO - 10.1002/art.10163

M3 - Article

VL - 46

SP - 1086

EP - 1093

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 4

ER -